Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

A Study to Evaluate the Absorption, Distribution, Metabolism, and Excretion of [14C]-MRM-3379

← catalyst calendar

NCT07712718

Sponsored by Mirum Pharmaceuticals, Inc. (industry) · MIRM — their whole pipeline →.

Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Na · None · Basic science
Enrollment
8estimated
Sites
1
Country
United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2026-05-29actualWhen the study began enrolling
Primary completionJul 2026estimatedThe date the last participant is measured for the primary outcome — the readout window
Study completionJul 2026estimatedThe whole study's end, after follow-up
First posted2026-07-17actualWhen this record first appeared on the registry
Results postedWhen the sponsor posted results to the registry
Record updated2026-07-17actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

  • Healthy Volunteers

Intervention

  • Drug: [14C]-MRM-3379 — also filed as MRM-3379

Primary outcomes

what the primary-completion date above is the date OF
Total radioactivity recovery of MRM-3379 in urine and feces
measured Up to 11 days post dose
Maximum observed concentration (Cmax) of MRM-3379 and 2 metabolites in plasma
measured Up to 11 days post dose
Time to maximum observed concentration (tmax) of MRM-3379 and 2 metabolites in plasma
measured up to 11 days post dose
Area under the concentration-time curve from time zero to the last quantifiable concentration (AUC0-tlast) of MRM-3379 and 2 metabolites in plasma
measured up to 11 days post dose
Maximum observed concentration (Cmax) of total radioactivity in plasma and whole blood
measured up to 11 days post dose
Time to maximum observed concentration (tmax) of total radioactivity in plasma and whole blood
measured up to 11 days post dose
Area under the concentration-time curve from time zero to the last quantifiable concentration (AUC0-tlast) of total radioactivity in plasma and whole blood
measured Up to 11 days post dose
Amount of MRM-3379 and 2 metabolites excreted in the urine (Ae) over sampling period
measured Up to 11 days post dose
Fraction of MRM-3379 and 2 metabolites excreted in the urine (Fe) as Ae/dose
measured Up to 11 days post dose
Renal clearance of MRM-3379 as Ae/AUC
measured Up to 11 days post dose

Permalink · MIRM's whole pipeline · Catalyst calendar · Every registered study · What changed